洞察
Insights From Our Experts
Articles
Capital Efficient Commercialization: A New Model for Success
In today’s fiscal environment, efficient capital allocation is crucial for success. Biopharma companies can take advantage of new approaches to commercialization to dramatically reduce the capital burden to launch their products. Building Your Own Commercial Infrastructure…
Enhancing Medical Strategies Through Effective Literature Surveillance
Posted by Mary Mehrabian, PharmD, BCGP, BCMAS , Michael DeLuca, PharmD, MBA, MSRA , Varun Pandey, PhD on 3月 13, 20253/13/25
Members from EVERSANA’s Medical Affairs (MA) team conducted a comprehensive survey to understand the needs of MA professionals regarding literature surveillance, reviews and alerts. They presented their findings at the DIA Medical Affairs and Scientific Communications…
Revolutionizing Customer Experience: The Role of AI in Enhancing MI Contact Center Operations
Posted by Carolyn Quon, PharmD , Michael DeLuca, PharmD, MBA, MSRA , Varun Pandey, PhD on 3月 13, 20253/13/25
At the 2025 DIA Medical Affairs and Scientific Communications Forum, experts from EVERSANA gave a presentation on the transformative role of AI in enhancing Medical Information (MI) Contact Center operations and its primary objective – to…
Trends Shaping Direct to Patient in Pharma
Direct-to-patient (DTP) models are being utilized more and more in recent years. While this provides pharma companies with new opportunities to reach patient populations, it also creates new complications that they need to find solutions for.…
Making Cutting-Edge Cancer Treatments Accessible: Advancing CAR-T Therapy to the Community Practice
Posted by Anne Marie Robertson , Barry Vucsko , Jordan Schell , Vanith Sankaran, PhD , Jordan Hayes on 3月 12, 20253/12/25
This article explores the significant advancements in CAR-T therapy and its transition from academic centers to community practices. CAR-T therapy, a revolutionary treatment for certain hematological malignancies, involves modifying a patient’s T-cells to target and destroy…
The Path to Maximizing Revenue: How to Simplify Pharmaceutical Commercialization and Find Optimum Success
For pharmaceutical manufacturers, achieving optimal revenue in a competitive landscape is a multifaceted challenge that requires strategic foresight and meticulous execution. Small and emerging biotech companies often face significant hurdles in reaching maximum commercial success. In…
Successfully Navigating the Complexity of Market Access Across Europe to Improve Health Equity
Navigating the complexities of bringing new drug therapies to market in Europe is a formidable challenge, especially with the diverse and fragmented reimbursement landscape across the EU’s 27 member states. In this insightful article published in…
Securing Launch Success Within the Context of the New EU Health Technology Assessment Regulation (HTAR) Landscape in Europe
The EU Health Technology Assessment Regulation (HTAR), effective from January 12, 2025, aims to harmonize the evaluation of health technologies across member states to enhance patient access to innovative treatments. In this latest article from Pamela…
Transformative Commercialization for New Biopharma Entrants: Ensuring Success With Capital and Time Efficiency
Posted by Maneesh Gupta , Matt Doyle , Nolan Kleinhenz , Andrew Therrien, PhD , Emily Bradshaw on 2月 21, 20252/21/25
Discover the transformative power of EVERSANA’s innovative commercialization model in our latest white paper. This essential guide is perfect for pharmaceutical companies, particularly first-time launchers, aiming to navigate the complexities of product commercialization. It addresses the…
Next-Generation Brand Planning: Some (Unexpected) Worrying Trends Demand a Rethink on Brand Planning
In our third annual report on the state of brand planning, EVERSANA surveyed nearly 100 brand planning executives across biopharmaceuticals, diagnostics and medical devices. This year, we expanded our assessment by hosting 111 marketing leaders from…